Literature DB >> 8330205

Long-term caffeine treatment leads to a decreased susceptibility to NMDA-induced clonic seizures in mice without changes in adenosine A1 receptor number.

V Georgiev1, B Johansson, B B Fredholm.   

Abstract

The effects of long-term caffeine treatment on N-methyl-D-aspartate (NMDA)-induced seizures in mice were studied. Caffeine was added (0.3 g/l) to drinking water for 14 days and the mice ingested 60-70 mg/kg/day. During the treatment, the plasma concentrations of methylxanthines (caffeine, theophylline and/or paraxanthine, theobromine) were measured. NMDA (150 mg/kg i.p.) was administered to control mice and to mice during and after the caffeine administration. A1 adenosine receptor density in the gyrus dentatus of hippocampus, measured by quantitative receptor autoradiography with [3H]cyclohexyl adenosine as the ligand, was not significantly altered after long-term caffeine treatment. NMDA-induced clonic seizures, wet dog shakes and mortality were significantly reduced at the end of long-term caffeine treatment but returned towards control at 1 and 2 days after withdrawal. At the end of caffeine treatment, tonic seizures were also absent. These results show that long-term treatment with caffeine in a dose that gives plasma levels of 6-10 microM decreases the effects of NMDA on e.g. seizure susceptibility, and that this effect cannot be ascribed to changes of A1 adenosine receptor density.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8330205     DOI: 10.1016/0006-8993(93)91672-f

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

Review 1.  Adenosine receptors and caffeine in retinopathy of prematurity.

Authors:  Jiang-Fan Chen; Shuya Zhang; Rong Zhou; Zhenlang Lin; Xiaohong Cai; Jing Lin; Yuqing Huo; Xiaoling Liu
Journal:  Mol Aspects Med       Date:  2017-01-11

Review 2.  Caffeine use in children: what we know, what we have left to learn, and why we should worry.

Authors:  Jennifer L Temple
Journal:  Neurosci Biobehav Rev       Date:  2009-01-20       Impact factor: 8.989

3.  Changes in the biochemical profiles of mid-cervically located adenosine A1 receptors after repeated theophylline administration in adult rats.

Authors:  Rubabe S Saharan; Kwaku D Nantwi
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

4.  Chronic effects of xanthines on levels of central receptors in mice.

Authors:  D Shi; J W Daly
Journal:  Cell Mol Neurobiol       Date:  1999-12       Impact factor: 5.046

5.  Caffeine preferentially protects against oxygen-induced retinopathy.

Authors:  Shuya Zhang; Rong Zhou; Bo Li; Haiyan Li; Yanyan Wang; Xuejiao Gu; Lingyun Tang; Cun Wang; Dingjuan Zhong; Yuanyuan Ge; Yuqing Huo; Jing Lin; Xiao-Ling Liu; Jiang-Fan Chen
Journal:  FASEB J       Date:  2017-04-18       Impact factor: 5.191

6.  The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions.

Authors:  P Svenningsson; G G Nomikos; B B Fredholm
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

7.  Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia.

Authors:  D K Von Lubitz; R C Lin; N Melman; X D Ji; M F Carter; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1994-04-21       Impact factor: 4.432

Review 8.  Recovery of respiratory activity after C2 hemisection (C2HS): involvement of adenosinergic mechanisms.

Authors:  Kwaku D Nantwi
Journal:  Respir Physiol Neurobiol       Date:  2009-08-03       Impact factor: 1.931

9.  Effects of Preinjury and Postinjury Exposure to Caffeine in a Rat Model of Traumatic Brain Injury.

Authors:  Theresa A Lusardi; Nikki K Lytle; Hoda M Gebril; Detlev Boison
Journal:  J Caffeine Adenosine Res       Date:  2020-03-04

10.  Regulation of cerebrospinal fluid production by caffeine consumption.

Authors:  Myoung-Eun Han; Hak-Jin Kim; Young-Suk Lee; Dong-Hyun Kim; Joo-Taek Choi; Chul-Sik Pan; Sik Yoon; Sun-Yong Baek; Bong-Seon Kim; Jae-Bong Kim; Sae-Ock Oh
Journal:  BMC Neurosci       Date:  2009-09-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.